Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer

Umang Swami; Emmanuel S. Antonarakis; Neeraj Agarwal

doi:10.1016/j.eururo.2020.12.009

Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer

Umang Swami
, Emmanuel S. Antonarakis
, Neeraj Agarwal

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e94-e95
Journal	European Urology
Volume	79
Issue number	3
DOIs	https://doi.org/10.1016/j.eururo.2020.12.009
State	Published - Mar 1 2021
Externally published	Yes

Keywords

Biomarkers
Castration
Humans
Male
Mutation
Nuclear Proteins
Precision Medicine
Prostatic Neoplasms
Repressor Proteins

PubMed: MeSH publication types

Comment
Letter

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.eururo.2020.12.009

Find It

Find It at U of M Libraries

Cite this

Swami, U., Antonarakis, E. S., & Agarwal, N. (2021). Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. European Urology, 79(3), e94-e95. https://doi.org/10.1016/j.eururo.2020.12.009

Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. / Swami, Umang; Antonarakis, Emmanuel S.; Agarwal, Neeraj.
In: European Urology, Vol. 79, No. 3, 01.03.2021, p. e94-e95.

Research output: Contribution to journal › Letter › peer-review

Swami, U, Antonarakis, ES & Agarwal, N 2021, 'Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer', European Urology, vol. 79, no. 3, pp. e94-e95. https://doi.org/10.1016/j.eururo.2020.12.009

Swami U, Antonarakis ES, Agarwal N. Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. European Urology. 2021 Mar 1;79(3):e94-e95. doi: 10.1016/j.eururo.2020.12.009

Swami, Umang ; Antonarakis, Emmanuel S. ; Agarwal, Neeraj. / Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re : Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. In: European Urology. 2021 ; Vol. 79, No. 3. pp. e94-e95.

@article{ddeb5d15680d4937b52cbdc4f031d237,

title = "Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer",

keywords = "Biomarkers, Castration, Humans, Male, Mutation, Nuclear Proteins, Precision Medicine, Prostatic Neoplasms, Repressor Proteins",

author = "Umang Swami and Antonarakis, \{Emmanuel S.\} and Neeraj Agarwal",

year = "2021",

month = mar,

day = "1",

doi = "10.1016/j.eururo.2020.12.009",

language = "English (US)",

volume = "79",

pages = "e94--e95",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "3",

}

TY - JOUR

T1 - Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re

T2 - Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer

AU - Swami, Umang

AU - Antonarakis, Emmanuel S.

AU - Agarwal, Neeraj

PY - 2021/3/1

Y1 - 2021/3/1

KW - Biomarkers

KW - Castration

KW - Humans

KW - Male

KW - Mutation

KW - Nuclear Proteins

KW - Precision Medicine

KW - Prostatic Neoplasms

KW - Repressor Proteins

UR - https://www.scopus.com/pages/publications/85099653534

UR - https://www.scopus.com/pages/publications/85099653534#tab=citedBy

U2 - 10.1016/j.eururo.2020.12.009

DO - 10.1016/j.eururo.2020.12.009

M3 - Letter

C2 - 33419681

AN - SCOPUS:85099653534

SN - 0302-2838

VL - 79

SP - e94-e95

JO - European Urology

JF - European Urology

IS - 3